TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Clover Biopharmaceuticals Ltd. ( (HK:2197) ) has issued an announcement.
Clover Biopharmaceuticals Ltd. announced the U.S. FDA clearance for its Investigational New Drug application and the initiation of a Phase I revaccination clinical trial for its RSV vaccine candidate, SCB-1019. This trial, enrolling older adults who previously received GSK’s RSV vaccine, aims to evaluate the safety and immunogenicity of SCB-1019. The company is also planning a Phase I trial in 2025 for a combination vaccine involving RSV and other respiratory viruses, indicating its strategic expansion in the vaccine market.
More about Clover Biopharmaceuticals Ltd.
Clover Biopharmaceuticals Ltd. is a company in the biotechnology industry, focusing on the development of innovative vaccines and biologics. It utilizes its proprietary Trimer-Tag vaccine technology platform to create vaccine candidates, with a market focus on addressing infectious diseases.
YTD Price Performance: 34.85%
Average Trading Volume: 1,618,911
Technical Sentiment Signal: Hold
Current Market Cap: HK$421.5M
Find detailed analytics on 2197 stock on TipRanks’ Stock Analysis page.